Consultation to strengthen vitamin B6 labelling for low-risk medicines
05th November 2026
The TGA is seeking feedback on a proposal to strengthen the labelling of low-risk products that contain vitamin B6.
This includes stronger warning statements and clearer labelling that indicates the presence and amount of vitamin B6 in these products.
The public consultation forms part of their efforts to help Australians reduce excessive vitamin B6 intake. Too much of this vitamin can increase the risk of nerve damage, which can cause severe, debilitating and potentially long-term effects.
If introduced, new labelling requirements would apply to listed medicines that contain vitamin B6, specifically the following ingredients:
- pyridoxine hydrochloride
- pyridoxal 5-phosphate
- pyridoxal 5-phosphate monohydrate.
The proposed labelling changes follow their decision to strengthen access controls. From 1 June 2027, oral vitamin B6 preparations that contain more than 50 mg to 200 mg per recommended daily dose will become 'Pharmacist only medicines' that must be stored behind the counter.